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BACKGROUND: Recommendations for diabetes preven-
tion in patients with prediabetes include lifestyle mod-
ification and metformin. However, the significance of
early weight loss and glucose measurements when
monitoring response to these proven interventions is
unknown.
OBJECTIVE: To quantify the relationship between early
measures of weight and glucose and subsequent diabetes
in patients undergoing diabetes prevention interventions.
DESIGN: Analysis of results from a randomized con-
trolled trial in 27 academic medical centers in the
United States.
PARTICIPANTS/INTERVENTIONS: 3,041 adults with
hyperglycemia randomized to lifestyle (n=1,018), met-
formin (n=1,036), or placebo (n=987) with complete
follow-up in The Diabetes Prevention Program.
MAIN MEASURES: Independent variables were weight
loss at 6 and 12months; fasting glucose (FG) at 6months;
hemoglobin A1c (HbA1c) at 6 months; and post-load
glucose at 12 months. The main outcome was time to
diabetes diagnosis.
KEY RESULTS: After 6 months, 604 participants devel-
oped diabetes in the lifestyle (n=140), metformin (n=206),
and placebo (n=258) arms over 2.7 years. In the lifestyle
arm, 6-month weight loss predicted decreased diabetes
risk in a graded fashion: adjustedHR (95%CI) 0.65 (0.35–
1.22), 0.62 (0.33–1.18), 0.46 (0.24–0.87), 0.34 (0.18–
0.64), and 0.15 (0.07–0.30) for 0–<3 %, 3–<5 %, 5–<7 %,
7–<10 %, and ≥10 % weight loss, respectively (reference:
weight gain). Attainment of optimal 6-month FG and
HbA1c and 12-month post-load glucose predicted >60 %
lower diabetes risk across arms. We found a significant
interaction between 6-month weight loss and FG in the
lifestyle arm (P=0.038).
CONCLUSION: Weight and glucose at 6 and
12 months strongly predict lower subsequent diabe-
tes risk with a lifestyle intervention; lower FG pre-
dicts lower risk even with substantial weight loss.
Early reduction in glycemia is a stronger predictor of
future diabetes risk than weight loss for metformin.
We offer the first evidence to guide clinicians in
making interval management decisions for high-risk
patients undertaking measures to prevent diabetes.
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INTRODUCTION
The Diabetes Prevention Program (DPP) demonstrated that
lifestyle modification and metformin decrease diabetes risk,
by 58 % and 31 %, respectively, relative to control over
3.2 years and by 34 % and 18 %, respectively, at 10 years of
follow-up.1,2 Prior research in the DPP established that
weight loss (more than physical activity) mediates the
beneficial effects of lifestyle change,3 and that both weight
loss and reduced glycemia mediate the beneficial effects of
metformin.4 These analyses indicate the contribution of
average weight loss over a 3-year period to the success of
the trial’s interventions. However, clinicians see their
patients at high risk of diabetes at least yearly, if not more
frequently. Our current analysis builds on the previous ones
to identify intermediary markers of success with regards to
weight and glucose parameters for the prevention or delay
of diabetes over a 3-year period.
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The American Diabetes Association recommends that
clinicians refer patients with impaired glucose tolerance,
impaired fasting glucose, or a hemoglobin A1c (HbA1c) of
5.7 % to 6.4 % for lifestyle interventions aimed at 7 % weight
loss and 150 min per week of moderate physical activity.5
Metformin is recommended for very high-risk patients.5 To
date, evidence is lacking on how to evaluate the response to
diabetes prevention interventions, which high-risk patients
should be considered candidates for metformin, and at what
point a given intervention should be intensified.
We analyzed data from theDPPwith the following aims: 1) To
quantify the association between early changes in body weight,
fasting glucose, HbA1c (first 6 months), and post-load glucose
(first 12 months) and the subsequent risk of diabetes at 3 years;
and 2) To identify joint patterns of weight loss and glycemic
reduction that indicate that diabetes risk has been minimized. We
hypothesized that greater reductions in weight and glycemic
markers after 6 and 12 months of intervention would be
associated with lower diabetes risk at 3 years and could help
guide physicians and patients in their diabetes prevention efforts.
METHODS
TheDPPwas amulti-center, randomized, placebo-controlled trial
that compared the effect of two active interventions (intensive
lifestyle modification or metformin) to a placebo medication
condition combined with standard lifestyle recommendations on
diabetes risk.1 Recruitment of overweight participants in the
United States with both impaired glucose tolerance and elevated
fasting glucose occurred between 1996 and 1999, and mean
follow-up was 3.2 years.1 The methods and main results of the
DPP were published previously.1 The current study evaluates the
relationship between early (≤12 months) measures of weight and
glucose homeostasis and 3-year diabetes risk in the DPP.
Setting and Participants
We included participants randomized to the intensive lifestyle
modification, metformin, or placebo arm without incident
diabetes at the follow-up time point of interest. For analyses of
weight, fasting glucose, and HbA1c at 6 months, we excluded
participants with incident diabetes at 6 months; for the analysis
of glucose tolerance at 12months, we excluded participants with
incident diabetes at 12 months. Participants missing data on
variables of interest were excluded. Final sample size was 3,041
for 6-month analyses and 2,853 for 12-month analyses (Fig. 1).
Randomization and Interventions
Randomizationwas adaptive and stratified by site.6 Investigators
and participants were masked to metformin and placebo, but not
the lifestyle intervention.1
The goals of the intensive lifestyle intervention were ≥7 %
weight loss and ≥150 min/week of moderate-intensity
physical activity.1
Metformin was started at 850 mg by mouth once daily and
increased to twice daily, and control arm participants took a
placebo twice daily.1 Participants in the metformin and
placebo arms arm received standard lifestyle recommenda-
tions at brief annual in-person sessions.1
Fasting glucose (FG) and weight were measured every
6 months in the DPP.1 Hemoglobin A1c was measured at
6 months and then annually.1 Oral glucose tolerance tests were
performed annually and consisted of administration of a 75-g
glucose load orally after a 12-h fast.1 The glucose measured 2 h
after the oral glucose load is the measure of glucose tolerance
that we term the “post-load glucose.”Weight was measured in
duplicate by trained, certified staff using a balance scale and a
standardized protocol.
Participants self reported age, sex, race/ethnicity (Caucasian,
African American, Hispanic, Asian, and American Indian),
education (≤12 years, 13–16 years, ≥17 years), and annual
household income (<$50,000 and ≥$50,000) at the baseline visit.1
The primary outcome of the DPP and the current study was
time to new diagnosis of diabetes defined by a FG ≥126 mg/
dL or post-load glucose ≥200 mg/dL, with confirmation by a
second test.1 Investigators, participants, and their physicians
were informed of results if a diagnosis of diabetes was made.1
Participants provided informed consent, and the study
protocol was approved by the Institutional Review Board at
each site. The funding source did not have a role in this sub-
analysis of the DPP.
Statistical Analysis
We compared baseline characteristics and differences in
glucose, percent weight change, and hemoglobin A1c using
Wilcoxon rank sum tests for continuous measures and chi-
square tests for categorical measures.
We used separate Cox proportional hazard models to
estimate hazard ratios for time to diabetes for four indepen-
dent variables: Percent weight change at 6 months, FG at
6 months, HbA1c at 6 months, and post-load glucose at
12 months. These were modeled continuously and categor-
ically. We defined clinically-relevant categories based on
current and past recommendations5,7,8: percent weight loss,
<0 % or weight gain (reference), 0 to <3 %, 3 to <5 %, 5 to
<7 %, 7 to <10 %, and ≥10 %; fasting glucose, ≥110 mg/dL
(reference), 100 to <110 mg/dL, and <100 mg/dL; hemoglo-
bin A1c, ≥6.5 % (reference), 5.7 to 6.4 %, and <5.7 %; and
post-load glucose, ≥140 mg/dL (reference) and <140 mg/dL.
We performed global tests for interactions between these
independent variables (treated as continuous variables) and
treatment arm, and then stratified analyses by arm if P for
interaction between the independent variables and treatment
arms was <0.05. When the proportional hazards assumption
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was violated, we adjusted the covariance matrix using Lin
and Wei’s robust sandwich estimates.9 We adjusted Cox
proportional hazards models for age, sex, race/ethnicity,
education, income, and the baseline measure of the indepen-
dent variable. When models were not stratified by treatment
arm, we included treatment arm as a covariate. The starting
time point for each model was as follows: 6 months for
analyses of 6-month weight change, fasting glucose, and
HbA1c and 12 months for analyses of post-load glucose.
We also calculated crude incidence rates of diabetes by
percentage of weight change and glucose categories and
used unadjusted Poisson regression to assess the statistical
significance of interactions between percent weight change
and glucose homeostasis.
We performed all analyses with SAS, version 9.2 (Cary,
North Carolina).
RESULTS
Baseline characteristics of the 3,041 study participants were
similar in the three treatment arms (Table 1). Compared to the
193 participants excluded because of diabetes at 6 months or
lack of follow-up data, the included participants were on
average older; more likely to be Caucasian and less likely to be
African American or Hispanic; and mean HbA1c, FG, and
weight were lower (Online Appendix Table 1).
Short-Term Weight Loss, Fasting Glucose,
and Post-Load Glucose
Mean percent weight loss at 6 months was 7.2 %, 2.4 %, and
0.4 % in the lifestyle, metformin and placebo arms, respec-
tively (Table 2). Almost all (92 %) participants in the lifestyle
arm lost weight at 6 months, while >25% of participants in the
metformin arm and nearly 50 % of those in the placebo arm
gained weight at 6 months. Six-month FG and HbA1c were
similar across arms, and 12-month post-load glucose was
significantly lower in the lifestyle compared to metformin and
placebo arms (Table 2).
Relationship Between Short-Term Weight Loss
and Glucose Measures and Diabetes Risk
After the 6-month visit, 604 participants (n=140, 206, and 258
in the lifestyle, metformin, and placebo arms, respectively)
developed diabetes over the course of the study (mean follow-
up 2.7 years). Diabetes risk decreased by 10 % for each
percentage point of weight loss at 6 months in the lifestyle arm
(HR, 0.90 (95 % CI, 0.87 to 0.94)) independent of FG or
HbA1c achieved. This graded benefit of 6-month weight loss
Figure 1. Selection of study participants.
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persisted over the course of the study (Fig. 2). Weight loss also
predicted lower diabetes risk in the placebo [HR, 0.95 (95 %
CI, 0.92 to 0.98)], but not metformin arm [HR, 0.98 (95 % CI,
0.94 to 1.02)] (P interaction between treatment arms and
weight loss=0.0051; Fig. 2).
Lower 6-month FG and HbA1c and post-load glucose at
12 months were associated with similar, substantial graded
reductions in diabetes risk across arms (Table 3). In the
lifestyle and placebo arms, these glycemic measures predicted
diabetes risk independent of weight loss. Six-month HbA1c
and 12-month post-load glucose predicted diabetes risk
independent of weight loss in the metformin arm.
Interactions Between Short-Term Weight Loss
and Glucose Measures
In the lifestyle arm, attainment of FG <100 mg/dl at 6 months
predicted a similar diabetes risk reduction across 6-month
weight loss categories, whereas diabetes risk decreased with
increasing weight loss in those with FG ≥110 mg/dl at 6 months
(Fig. 3, P interaction from Poisson regression=0.038). Diabetes
risk was similar for those with the combination of ≥10%weight
loss and FG ≥110 mg/dL at 6 months (4.3, 95 % CI 1.5 to 12.4
cases/100 person-years) and those with a combination of weight
gain and fasting glucose <100 mg/dL at 6 months (3.4, 95 %CI
1.1 to 10.3 cases/100 person-years) (Fig. 3). Poisson models did
not reveal significant interactions between 6-month FG and
weight loss in the metformin or placebo arm or a significant
interaction between 6-month HbA1c and weight loss or 12-
month post-load glucose and weight loss in any arm.
DISCUSSION
In a population at high risk for type 2 diabetes undergoing
intensive lifestyle change, 6-month weight loss predicted lower
3-year diabetes risk in a graded fashion; compared with weight
gain, ≥10 % weight loss at 6 months was associated with an
85 % reduction in diabetes incidence at 3-year follow-up, and
early weight loss was especially important in reducing diabetes
risk among those with FG ≥110 mg/dl at 6 months. The effect
of ≥10 % weight loss at 6 months was not significant in the
metformin and placebo arms. Results for glucose and HbA1c
were similar across treatment arms (lifestyle, metformin, and
placebo); compared with higher values, achievement of fasting
glucose <100 mg/dl or HbA1c <5.7 % at 6 months or 12-
month post-load load glucose <140 mg/dl was associated with
a 62 to 70 % diabetes risk reduction.
Several points deserve mention regarding the interpreta-
tion of our findings. Few participants receiving metformin
lost >7 % of their baseline weight at 6 months with many
gaining weight, and more than 80 % of participants in the
placebo arm either gained weight or lost little weight at
6 months. This relative difference in weight loss across the
arms likely explains the clear graded benefit of weight loss
observed in the lifestyle arm compared to that in the
metformin and placebo arms, especially since early weight
loss in this lifestyle arm predicted maintenance of weight loss
over the course of the study.10 Also, we did not find a
statistically significant diabetes risk reduction for partici-
pants with less than 5 % weight loss at 6 months in the
lifestyle arm although HRs were suggestive of a benefit; this
lack of statistical significance is likely related to the small
samples for the 0–<3% and 3–<5%weight loss categories in
that arm. Therefore, it is likely that 6-month weight loss of
any amount is beneficial. Additionally, participants in the
lifestyle arm had much more in-person contact with case
managers which generally improves the effect of lifestyle
interventions.11,12 Participants experiencing substantial
weight loss in the lifestyle arm despite a high FG at 6 months
may have been more successful in continuing lifestyle
modification and eventually reducing diabetes risk as
suggested by prior analysis of the DPP10; this may partly
explain the interaction between weight loss and fasting
glucose at 6 months in predicting diabetes risk. Another
important consideration when comparing the three arms is
that attainment of the physical activity and dietary goals at
Table 1. Baseline Characteristics of Diabetes Prevention Program
Participants Without Diabetes at 6 Months (Participants Without
Complete Data Excluded from Analysis) (N=3,041)
Lifestyle
arm
Metformin
arm
Placebo
N 1,036 1,018 987
Age, median [IQR], y 50 [42, 59] 51 [44, 57] 50 [44, 57]
Sex, %
Women 69 66 69
Race, %
Caucasian 54 56 55
African American 18 20 20
Hispanic 16 15 15
Asian 6 3 5
American Indian 6 5 6
HbA1c, median
[IQR],%†
5.9 [5.6, 6.2] 5.9 [5.6, 6.2] 5.9 [5.6, 6.2]
<5.7 29 30 29
5.7 to <6.5 59 57 58
≥6.5 12 13 12
Fasting glucose,
median [IQR], mg/dL
105 [100, 111] 105 [100, 112] 105 [100, 111]
<100 20 21 21
100 to <110 49 46 48
≥110 31 33 31
Post-load glucose,
median [IQR], mg/dL†
162 [150, 177]163 [150, 179]162 [149, 177]
Weight, median
[IQR], kg
91 [79, 105] 91 [80, 105] 91 [79, 105]
Education, %
≤12 years 26 25 27
>12 years 74 75 73
Household income, %§
<$50,000 56 53 52
≥$50,000 44 47 48
IQR 25th percentile, 75th percentile; HbA1c hemoglobin A1c
*HbA1c results available for 3,034 participants
†Glucose level 2 h after administration of 75 g of an oral glucose load
‡2,802 (92 %) of participants provided income information
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12 months by participants in the lifestyle arm decreased
diabetes risk over the course of the study even in the absence
of attainment of the weight goal.3
A major strength of our analysis is that the DPP was a
well-conducted randomized trial with high overall follow-
up (92.5 %) and standardized measurement of all variables
reducing measurement error and enhancing internal valid-
ity.1 The study population was diverse by race/ethnicity and
age making our results generalizable to the U.S. population at
risk for type 2 diabetes. Also, the DPP assessed weight, fasting
glucose, and HbA1c at 6 months to evaluate success of the
interventions, a practice that can be readily assimilated in
clinical practice.
While the glucose measures collected at 6 and 12 months
are part of the case definition of diabetes and are therefore
expected to predict diabetes risk, these measures are recom-
mended in clinical practice to screen for diabetes.5,7 Thus,
quantifying the association between these measures and
longer-term risk of diabetes is paramount in understanding
the impact of preventive efforts. The lifestyle participants
enrolled in the DPP maintained substantial weight loss over
10 years, as demonstrated in the DPP-Outcomes Study,2
which may be more difficult for patients in clinical practice. At
the time of their most recent visit prior to the end of the DPP
(mean follow-up 2.8 years), 38% percent and 58% of lifestyle
participants had achieved the intervention weight loss and
physical activity goals, respectively,1 and 72 % of those in the
metformin arm took ≥80% of the medication during the DPP.1
We conducted an intention-to-treat analysis and did not
exclude participants based on adherence. This approach
should reflect the clinical effectiveness of these interventions
in practice.
Previous work in the Diabetes Prevention Program
showed a graded benefit of weight loss averaged over the
approximately 3 years of total follow-up in reducing
diabetes risk in the lifestyle, metformin, and placebo
arms.3,4 Lachin et al. demonstrated that change in fasting
glucose over the study duration was the strongest predictor
of diabetes risk in the metformin and placebo arms,
accounting for 14 % and 25 % of the decrease in risk over
the course of the study in these two arms, respectively.4
Among participants who had both impaired fasting glucose
and impaired glucose tolerance at baseline, each standard
deviation of mean weight loss was associated with a 34 %
increased probability of regression to normal glucose
regulation.13 We now extend our understanding of these
benefits by quantifying the predictive value of weight, glucose
and HbA1c during the first 12 months of a preventive effort,
and thereby inform approaches to intensifying preventive
therapies in clinical practice.
Table 2. Body Weight, Fasting Glucose, and HbA1c at 6 Months and Post-Load Glucose at 12 Months Following Randomization in the
Diabetes Prevention Program (Participants Without Complete Data Excluded from Analysis)
Lifestyle arm Metformin arm Placebo arm
Weight loss at 6 months
N 1,031 1,012 981
Median [IQR] weight loss, %† 7.2 [3.7, 10.5] 2.0 [−0.1, 4.7] 0.0 [−1.9, 2.3]
Category of weight loss†
<0 %, N (%) 79 (8) 264 (26) 481 (49)
0 to <3 %, N (%) 144 (14) 342 (34) 310 (32)
3 to <5 %, N (%) 137 (13) 179 (18) 88 (9)
5 to <7 %, N (%) 146 (14) 100 (10) 45 (5)
7 to <10 %, N (%) 232 (23) 80 (8) 33 (3)
≥10 %, N (%) 293 (28) 47 (5) 24 (2)
Fasting glucose at 6 months
N 1,035 1,017 984
Fasting glucose, median [IQR] mg/dLb 101 [95, 107] 101 [95, 108] 104 [98, 112]
Category of fasting glucose†
≥110 mg/dL, N (%) 184 (18) 211 (21) 333 (34)
100 to <110 mg/dL, N (%) 396 (38) 362 (36) 363 (37)
<100 mg/dL, N (%) 455 (44) 444 (44) 288 (29)
HbA1c at 6 months
N 1,031 1,012 980
HbA1c, median [IQR], %† 5.8 [5.5, 6.1] 5.8 [5.6, 6.1] 5.9 [5.6, 6.3]
Category of HbA1c*
≥6.5 %, N (%) 75 (7) 87 (9) 154 (16)
5.7 to 6.4 %, N (%) 497 (48) 502 (50) 487 (50)
<5.7 %, N (%) 459 (45) 423 (42) 339 (35)
Post-load glucose at 12 months
N 1,001 956 896
Post-load glucose, median [IQR], mg/dL†,‡ 137 [114, 160] 153 [127, 176] 150 [128, 174]
Category of post-load glucoseb,c
≥140 mg/dL, N (%) 449 (46) 575 (63) 574 (64)
<140 mg/dL, N (%) 520 (54) 336 (37) 320 (36)
IQR 25th percentile, 75th percentile; HbA1c hemoglobin A1c
*P<0.0001 comparing lifestyle, metformin, and placebo arms using Wilcoxon rank sum tests to compare medians and chi square tests to compare
proportions
†Glucose level 2 h after administration of 75 g of an oral glucose load
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Figure 2. Diabetes risk in the Diabetes Prevention Program in each treatment arm by percent weight loss at achieved at 6 months. Hazard
ratios for diabetes after 6 months in the Diabetes Prevention Program (mean follow-up 2.7 years) adjusted for the following: Age, sex, race/
ethnicity, education, income, and baseline weight. Each category of percentage of weight loss achieved at 6 months is compared to the
reference group consisting of participants who gained weight (weight loss <0 %) at the 6-month visit. Participants with incident diabetes at
the 6-month follow-up visit are excluded.
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Current guidelines for diabetes prevention recommendweight
loss and physical activity for at-risk patients and consideration of
metformin for those at highest risk, but offer minimal guidance
on escalation of preventive therapy.5 Our results suggest that
both the weight loss and glycemic status achieved at 6 months
are indicators of long-term success in diabetes prevention.
Extrapolating to the clinic setting, these factors may be
considered at 6 months to determine efficacy of the intervention.
For example, our analyses suggest that individuals who achieve
modest weight loss alone (e.g., 3–5 %) with intensive lifestyle
intervention, but whose fasting glucose levels remain greater
than 100 mg/dl at 6 months, would still be at increased risk of
conversion to diabetes (Fig. 3), and addition of metformin may
be considered. On the other hand, patients attaining ≥10 %
weight loss and fasting glucose <100 mg/dl at 6 months have
likely decreased their risk substantially (Fig. 3), and could be
reassured about their preventive efforts. There is need for further
study of the appropriate time points for and methods of
escalation of therapy, and our analyses provide the data to
support the design of such studies.
Evidence on type 2 diabetes prevention strategies is
extensive,1,14–16 and currently, clinicians in the United States
seeking to help patients reduce their diabetes risk recommend
lifestyle change and monitor weight, fasting glucose, and/or
HbA1c levels periodically. Among persons undergoing
lifestyle change, we show that greater weight loss at 6 months
predicts decreased 3-year diabetes risk in a graded fashion
and that achievement of fasting glucose <100 mg/dl at
6 months is beneficial regardless of weight loss. Glucose
measures are the strongest indicators of successfully reduced
diabetes risk with metformin. Our study offers the first
evidence to guide clinicians in making interval management
decisions for patients at high risk for diabetes undertaking
preventive measures.
Table 3. Hazard Ratios (95 % CI) for Diabetes by Fasting Glucose
or HbA1c Achieved at 6 Months or Post-Load Glucose Achieved
at 12 Months Following Randomization (Mean Follow-Up for
Analyses at 6 Months, 2.7 Years and Mean Follow-Up for Analyses
at 12 months, 2.2 years) Across Arms [Results are Not Stratified
by Treatment Arm Because the Association Between Glucose
Measures and Diabetes Risk Did Not Vary Significantly by
Treatment Arm (P for Global Test of Interaction 0.75 for Fasting
Glucose, 0.42 for HbA1c, and 0.91 for Post-Load Glucose)] in the
Diabetes Prevention Program
HR (95 % CI) for
diabetes risk*
Per 5 mg/dL decrement of fasting
glucose at 6 months
0.74 (0.70, 0.79)
Category of fasting glucose at 6 months
<100 mg/dL 0.31 (0.24, 0.40)
100 to <110 mg/dL 0.37 (0.29, 0.46)
≥110 mg/dL 1.0
Per 0.5 % decrement of HbA1c at 6 months 0.58 (0.48,0.69)
Category of HbA1c at 6 months
<5.7 % 0.38 (0.25, 0.57)
5.7 to 6.4 % 0.50 (0.38, 0.66)
≥6.5 % 1.0
Per 5 mg/dL decrement of post-load
glucose at 12 months§
0.90 (0.88–0.92)
Category of post-load glucose at 12 months
<140 mg/dL 0.30 (0.22, 0.40)
≥140 mg/dL 1.0
HbA1c hemoglobin A1c
*All hazard ratios are adjusted for treatment arm, age, sex, race/
ethnicity, education, household income, and the baseline measure of
the independent variable
†Glucose level 2 h after administration of 75 g of an oral glucose load
Figure 3. Diabetes incidence during the Diabetes Prevention Program in each treatment arm by weight loss and fasting glucose achieved at
6 months. Crude diabetes incidence rates over the course of the Diabetes Prevention Program by weight loss and fasting glucose achieved at
6 months (mean follow-up 2.7 years). Test for interaction between weight loss and fasting glucose at 6 months from Poisson regression
model: P=0.038 (lifestyle), P=0.586 (metformin), and P=0.285 (placebo). Participants with incident diabetes at the 6-month follow-up visit
are excluded.
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